1 June 2023 false Taxfiler 2024.6 true 08925012business:PrivateLimitedCompanyLtd2023-06-012024-05-31 089250122023-05-31 089250122023-06-012024-05-31 08925012business:AuditExemptWithAccountantsReport2023-06-012024-05-31 08925012business:FilletedAccounts2023-06-012024-05-31 089250122024-05-31 08925012business:Director12023-06-012024-05-31 08925012business:RegisteredOffice2023-06-012024-05-31 089250122023-05-31 08925012core:WithinOneYear2024-05-31 08925012core:WithinOneYear2023-05-31 08925012core:AfterOneYear2024-05-31 08925012core:AfterOneYear2023-05-31 08925012core:ShareCapitalcore:PreviouslyStatedAmount2024-05-31 08925012core:ShareCapitalcore:PreviouslyStatedAmount2023-05-31 08925012core:CapitalContributionReservecore:PreviouslyStatedAmount2024-05-31 08925012core:CapitalContributionReservecore:PreviouslyStatedAmount2023-05-31 08925012core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-05-31 08925012core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2023-05-31 08925012core:PreviouslyStatedAmount2024-05-31 08925012core:PreviouslyStatedAmount2023-05-31 08925012business:SmallEntities2023-06-012024-05-31 08925012countries:EnglandWales2023-06-012024-05-31 08925012core:ComputerEquipment2023-06-012024-05-31 08925012core:ComputerEquipment2023-05-31 08925012core:ComputerEquipment2024-05-31 08925012core:WithinOneYear2023-06-012024-05-31 08925012core:AfterOneYear2023-06-012024-05-31 089250122022-06-012023-05-31 iso4217:GBP xbrli:pure
Company Registration No. 08925012 (England and Wales)
Angulus Pharma Limited Unaudited accounts for the year ended 31 May 2024
Angulus Pharma Limited Unaudited accounts Contents
Page
- 2 -
Angulus Pharma Limited Company Information for the year ended 31 May 2024
Director
Dr Albert Chan
Company Number
08925012 (England and Wales)
Registered Office
128 City Road London EC1V 2NX
Accountants
Wellington Consulting Ltd Fairview St Owens Cross Hereford Herefordshire HR2 8LG
- 3 -
Angulus Pharma Limited Accountants' report
Accountants' report to the director of Angulus Pharma Limited on the preparation of the unaudited statutory accounts for the year ended 31 May 2024
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Angulus Pharma Limited for the year ended 31 May 2024 as set out on pages 5 - 7 from the company's accounting records and from information and explanations you have given us.
This report is made solely to the Board of Directors of Angulus Pharma Limited, as a body, in accordance with the terms of our engagement. Our work has been undertaken solely to prepare for your approval the accounts of Angulus Pharma Limited and state those matters that we have agreed to state to them, as a body, in this report. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Angulus Pharma Limited and its Board of Directors as a body for our work or for this report.
It is your duty to ensure that Angulus Pharma Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of Angulus Pharma Limited. You consider that Angulus Pharma Limited is exempt from the statutory audit requirement for the year.
We have not been instructed to carry out an audit or a review of the accounts of Angulus Pharma Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.
Wellington Consulting Ltd Fairview St Owens Cross Hereford Herefordshire HR2 8LG 25 February 2025
- 4 -
Angulus Pharma Limited Statement of financial position as at 31 May 2024
2024 
2023 
Notes
£ 
£ 
Fixed assets
Tangible assets
250 
501 
Current assets
Debtors
3,858 
37 
Cash at bank and in hand
177 
37 
4,035 
74 
Creditors: amounts falling due within one year
(6,866)
(6,366)
Net current liabilities
(2,831)
(6,292)
Total assets less current liabilities
(2,581)
(5,791)
Creditors: amounts falling due after more than one year
(84,892)
(84,312)
Net liabilities
(87,473)
(90,103)
Capital and reserves
Called up share capital
100 
100 
Capital contribution reserve
260,935 
260,935 
Profit and loss account
(348,508)
(351,138)
Shareholders' funds
(87,473)
(90,103)
For the year ending 31 May 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 25 February 2025 and were signed on its behalf by
Dr Albert Chan Director Company Registration No. 08925012
- 5 -
Angulus Pharma Limited Notes to the Accounts for the year ended 31 May 2024
1
Statutory information
Angulus Pharma Limited is a private company, limited by shares, registered in England and Wales, registration number 08925012. The registered office is 128 City Road, London, EC1V 2NX.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets. The accounts have been prepared on a going concern basis as the director has confirmed that he will continue to provide financial support to the company to enable it to meet its financial liabilities for the foreseeable future.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives with an adjustment to correct an earlier year error:
Computer equipment
25% straight line basis
Foreign exchange
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rates of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
Going concern
The main creditor is the sole director and shareholder who does not intend seeking repayment until the company can afford to repay him.
- 6 -
Angulus Pharma Limited Notes to the Accounts for the year ended 31 May 2024
4
Tangible fixed assets
Computer equipment 
£ 
Cost or valuation
At cost 
At 1 June 2023
1,003 
At 31 May 2024
1,003 
Depreciation
At 1 June 2023
502 
Charge for the year
251 
At 31 May 2024
753 
Net book value
At 31 May 2024
250 
At 31 May 2023
501 
5
Debtors
2024 
2023 
£ 
£ 
Amounts falling due within one year
VAT
5 
37 
Trade debtors
3,853 
- 
3,858 
37 
6
Creditors: amounts falling due within one year
2024 
2023 
£ 
£ 
Trade creditors
4,617 
4,822 
Other creditors
2,149 
1,424 
Accruals
100 
120 
6,866 
6,366 
The trade creditors include two invoices under query to the value of £4,617.
7
Creditors: amounts falling due after more than one year
2024 
2023 
£ 
£ 
Loans from directors
84,892 
84,312 
The balance of £84,892 (2023 - £84,312) is due to the sole shareholder who does not seek repayment until the company is in a position to repay the loan.
8
Average number of employees
During the year the average number of employees was 1 (2023: 1).
- 7 -